Microbiology Devices; Reclassification of Influenza Virus Antigen Detection Test Systems Intended for Use Directly

    Federal Register
    |January 20, 2017
    PubMed

    Insights

    The Food and Drug Administration (FDA) is updating regulations for rapid influenza diagnostic tests. These antigen tests will move from Class I to Class II, requiring special controls for improved accuracy and patient safety.

    Area of Science:

    • Medical Diagnostics
    • Regulatory Science
    • Infectious Disease Testing

    Background:

    • Current regulation of antigen-based rapid influenza virus antigen detection test systems.
    • Existing classification as influenza virus serological reagents.
    • Need for updated regulatory pathways for diagnostic devices.

    Purpose of the Study:

    • To reclassify antigen-based rapid influenza virus antigen detection test systems.
    • To establish a new device classification regulation for these tests.
    • To implement special controls for enhanced regulatory oversight.

    Main Methods:

    • Review of existing regulatory classifications for diagnostic tests.
    • Assessment of performance characteristics of rapid influenza antigen detection systems.
    • Development of new regulatory framework incorporating special controls.

    Main Results:

    • Reclassification of rapid influenza antigen detection test systems from Class I to Class II.
    • Introduction of a new device classification regulation.
    • Establishment of specific special controls for these tests.

    Conclusions:

    • The reclassification aims to ensure the safety and effectiveness of rapid influenza diagnostic tests.
    • Implementation of special controls will enhance the reliability of influenza virus detection.
    • The new regulatory approach supports advancements in infectious disease diagnostics.

    Related Concept Videos